Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer

[1]  M. Barbacid,et al.  Targeting the MAPK Pathway in KRAS-Driven Tumors. , 2020, Cancer cell.

[2]  J. Iovanna,et al.  Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer , 2020, bioRxiv.

[3]  R. Deberardinis,et al.  Mechanisms and Implications of Metabolic Heterogeneity in Cancer. , 2019, Cell metabolism.

[4]  M. Adjobo-Hermans,et al.  Mitochondrial Morphofunction in Mammalian Cells. , 2019, Antioxidants & redox signaling.

[5]  A. Vincent-Salomon,et al.  PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers , 2019, Cell metabolism.

[6]  J. Winter,et al.  Metabolic Dependencies in Pancreatic Cancer , 2018, Front. Oncol..

[7]  B. Yan,et al.  Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer , 2018, Life sciences.

[8]  A. Kimmelman,et al.  The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[9]  H. Levine,et al.  Elucidating the Metabolic Plasticity of Cancer: Mitochondrial Reprogramming and Hybrid Metabolic States , 2018, Cells.

[10]  Geoff S. Higgins,et al.  Oxidative Phosphorylation as an Emerging Target in Cancer Therapy , 2018, Clinical Cancer Research.

[11]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[12]  J. Iovanna,et al.  Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts , 2017, Cell reports.

[13]  M. Carroll,et al.  Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. , 2017, Cancer discovery.

[14]  A. Maitra,et al.  Treatment of Pancreatic Cancer Patient–Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin , 2017, Clinical Cancer Research.

[15]  V. Mieulet,et al.  Heterogeneity in Cancer Metabolism: New Concepts in an Old Field , 2017, Antioxidants & redox signaling.

[16]  J. Qi,et al.  Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts , 2017, EMBO molecular medicine.

[17]  C. Lyssiotis,et al.  Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. , 2017, Cancer cell.

[18]  A. Saluja,et al.  Evolution of novel therapeutic options for pancreatic cancer , 2016, Current opinion in gastroenterology.

[19]  M. Soler‐Lopez,et al.  Dynamics of Human Mitochondrial Complex I Assembly: Implications for Neurodegenerative Diseases , 2016, Front. Mol. Biosci..

[20]  I. Kovalenko,et al.  Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines , 2016, PloS one.

[21]  Xun Hu,et al.  Lactic acidosis switches cancer cells from aerobic glycolysis back to dominant oxidative phosphorylation , 2016, Oncotarget.

[22]  A. Bhaw-Luximon,et al.  Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification , 2016, Journal of Cancer Research and Clinical Oncology.

[23]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[24]  C. Heeschen,et al.  MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. , 2015, Cell metabolism.

[25]  Anneleen Daemen,et al.  Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors , 2015, Proceedings of the National Academy of Sciences.

[26]  A. Zwinderman,et al.  Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. , 2015, The Lancet. Oncology.

[27]  J. Iovanna,et al.  A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor , 2014, Oncotarget.

[28]  John M. Asara,et al.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.

[29]  M. Pollak,et al.  Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria , 2014, The Biochemical journal.

[30]  M. Pollak.  Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment , 2014, Nature Medicine.

[31]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[32]  Andrea Glasauer,et al.  Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis , 2014, eLife.

[33]  D Saur,et al.  Oncogenic KRAS signalling in pancreatic cancer , 2014, British Journal of Cancer.

[34]  Channing J Der,et al.  KRAS: feeding pancreatic cancer proliferation. , 2014, Trends in biochemical sciences.

[35]  Y. Kloog,et al.  Metabolism addiction in pancreatic cancer , 2014, Cell Death and Disease.

[36]  Eileen White,et al.  Exploiting the bad eating habits of Ras-driven cancers , 2013, Genes & development.

[37]  Aune Moro,et al.  Metformin Inhibits the Growth of Human Pancreatic Cancer Xenografts , 2013, Pancreas.

[38]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[39]  S. F. Konieczny,et al.  Maintenance of Acinar Cell Organization is Critical to Preventing Kras-Induced Acinar-Ductal Metaplasia , 2012, Oncogene.

[40]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[41]  Kevin M. Ryan,et al.  p53 and metabolism , 2009, Nature Reviews Cancer.

[42]  Philippe Besse,et al.  Sparse canonical methods for biological data integration: application to a cross-platform study , 2009, BMC Bioinformatics.

[43]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[44]  M. Owen,et al.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.

[45]  S. Glaser,et al.  A general enhancement scheme in heteronuclear multidimensional NMR employing pulsed field gradients , 1994, Journal of biomolecular NMR.

[46]  M. Rance,et al.  Sensitivity improvement in isotropic mixing (TOCSY) experiments , 1990 .

[47]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.